The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
Abstract
CONTEXT: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown. OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss-induced bone mass reduction. DESIGN: Randomized control study. SETTING: Outpatient research hospital clinic. PARTICIPANTS: Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years. INTERVENTION: After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks. In case of weight gain, up to two meals per day could be replaced with a low-calorie-diet product to maintain the weight loss. MAIN OUTCOME MEASURES: Total, pelvic, and arm-leg bone mineral content (BMC) and bone markers [C-terminal telopeptide of type 1 collagen (CTX-1) and N-terminal propeptide of type 1 procollagen (P1NP)] were investigated before and after weight loss and after 52-week weight maintenance. Primary endpoints were changes in BMC and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment. RESULTS: Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95% confidence interval, 5-48; P = .01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7 ± 3 μg/L) vs a 2% (-1 ± 4 μg/L) decrease in the control group (P < .05). The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase. CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low-calorie diet, supporting its role as a safe weight-lowering agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In euglycemic individuals, liraglutide increased procollagen type I N-terminal propeptide (P-PINP) levels by 16%, compared with a 2% decrease in the placebo group [42].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [42]
In the citing paper
“Treatment with liraglutide has been shown to increase bone formation in body weight-reduced obese women when compared to placebo (14).”
In the citing paper
“The reduction in PINP in the exenatide-treated group contrasts a previously reported increase of PINP in obese women, who experienced a 12% body weight reduction after 12 months of liraglutide treatment (14).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationBone “mass” and the “mechanostat”: A proposal
Frost, H. M. (1987) · The Anatomical Record · doi:10.1002/ar.1092190104 · Cited by 2,132
Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture
Janghorbani, M., van Dam, R. M., Willett, W. C., & Hu, F. B. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm106 · Cited by 1,223
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553
Mechanical and textural properties of pelvic trabecular bone
Dalstra, M., Huiskes, R., Odgaard, A., & van Erning, L. (1993) · Journal of Biomechanics · doi:10.1016/0021-9290(93)90014-6 · Cited by 361
Bone Metabolism in Obesity and Weight Loss
Shapses, S. A., & Sukumar, D. (2012) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104655 · Cited by 358
Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption
Henriksen, D. B., Alexandersen, P., Bjarnason, N. H., Vilsbøll, T., Hartmann, B., Henriksen, E. E., Byrjalsen, I., Krarup, T., Holst, J. J., & Christiansen, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2180 · Cited by 331
Self-citationFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Self-citation
Research works printed but not linked: 1
- Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gas- trointestinal hormones in postprandial reduction of bone resorp- tion. J Bone Miner Res. 2003;18(12):2180 -2189.
Cited by
Sorted by citations
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Hygum, K., Starup‐Linde, J., Harsløf, T., Vestergaard, P., & Langdahl, B. L. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0652 · Cited by 334
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
Paschou, S. Α., Dede, A. D., Anagnostis, P. G., Vryonidou, A., Morganstein, D. L., & Goulis, D. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00042 · Cited by 206
Metadata
- Authors
- Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Iepsen, Eva W.
- Torekov, Signe S.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- 2909-2917
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1934495549
- Cited by
- 193
- References
- 54
- Citations by year
- 2026: 16 · 2025: 39 · 2024: 21 · 2023: 15 · 2022: 16 · 2021: 9 · 2020: 11 · 2019: 24 · 2018: 15 · 2017: 10 · 2016: 9 · 2015: 8
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Diabetes Academy
- Ministério da Ciência, Tecnologia e Inovação
- Novo Nordisk
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Faculty of Health and Medical Sciences, University of Western Australia
- Hvidovre Hospital
- Novo Nordisk Fonden (NNF14OC0009787)
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, bone loss, bone formation, weight loss, obesity, obese women, bone mineral content, bone turnover markers, P1NP, C-terminal telopeptide of type I collagen, hypocaloric diet, weight maintenance, glucagon-like peptide-1, osteoporosis prevention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Adolescent, Adult, Aged, Bone Resorption, Female, Humans, Middle Aged, Obesity, Osteogenesis, Weight Loss, Receptors, Glucagon, Caloric Restriction, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
